



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/055,713	01/22/2002	Andrew Jamieson	8325-0026	6239

20855 7590 05/10/2005

ROBINS & PASTERNAK
1731 EMBARCADERO ROAD
SUITE 230
PALO ALTO, CA 94303

EXAMINER

COLLINS, CYNTHIA E

ART UNIT PAPER NUMBER

1638

DATE MAILED: 05/10/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.		Applicant(s)	
	10/055,713		JAMIESON ET AL.	
	Examiner		Art Unit	
	Cynthia Collins		1638	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 10 June 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4, 6-11, 14, 17-19 and 21-33 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-4, 6-11, 14, 17-19 and 21-33 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a p300 functional domain, classified in class 536, subclass 23.4, for example.
- II. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a CBP functional domain, classified in class 536, subclass 23.4, for example.
- III. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a PCAF functional domain, classified in class 536, subclass 23.4, for example.
- IV. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further

encoding a SRC1 functional domain, classified in class 536, subclass 23.4, for example.

- V. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a PvALF functional domain, classified in class 536, subclass 23.4, for example.
- VI. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a ERF-2 functional domain, classified in class 536, subclass 23.4, for example.
- VII. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a OsGAI functional domain, classified in class 536, subclass 23.4, for example.
- VIII. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a HALF-1 functional domain, classified in class 536, subclass 23.4, for example.

- IX. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a C1 functional domain, classified in class 536, subclass 23.4, for example.
- X. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a AP1 functional domain, classified in class 536, subclass 23.4, for example.
- XI. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a ARF-5 functional domain, classified in class 536, subclass 23.4, for example.
- XII. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a ARF-6 functional domain, classified in class 536, subclass 23.4, for example.
- XIII. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide

Art Unit: 1638

encoding a modified zinc finger protein, said isolated polynucleotide further encoding a ARF-7 functional domain, classified in class 536, subclass 23.4, for example.

XIV. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a ARF-8 functional domain, classified in class 536, subclass 23.4, for example.

XV. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a CPRF1 functional domain, classified in class 536, subclass 23.4, for example.

XVI. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a CPRF4 functional domain, classified in class 536, subclass 23.4, for example.

XVII. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further

Art Unit: 1638

encoding a MYC-RP/GP functional domain, classified in class 536, subclass 23.4, for example.

XVIII. Claims 1-4, 6-11, 14, 17-19 and 21-33, drawn to a non-naturally occurring protein, an expression vector, a host cell, and an isolated polynucleotide encoding a modified zinc finger protein, said isolated polynucleotide further encoding a TRAB1 functional domain, classified in class 536, subclass 23.4, for example.

The inventions are distinct, each from the other because of the following reasons:

Each of inventions of Groups I-XVIII requires an additional separate area of search directed to specific protein functional domains (p300, CBP, PCAF, SRC1, PvALF, ERF-2, OsGAI, HALF-1, C1, AP1, ARF-5, ARF-6, ARF-7, ARF-8, CPRF1, CPRF4, MYC-RP/GP and TRAB1) that originate from different species of organisms and that differ both structurally and functionally.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by the requirement for different areas of search, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

Art Unit: 1638

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cynthia Collins whose telephone number is (571) 272-0794. The examiner can normally be reached on Monday-Friday 8:45 AM -5:15 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (571) 272-0804. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Cynthia Collins
Examiner
Art Unit 1638

CC

Cynthia Collins 5/3/05